- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 15.10.24 | Molecure inks $32 million deal with Ocean Biomedical for cancer therapy | 2 | Investing.com | ||
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 215 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
| 31.07.24 | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 407 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen | |
| 21.05.24 | Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway | 208 | GlobeNewswire (Europe) | OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases.Obtaining regulatory approvals... ► Artikel lesen | |
| 03.04.24 | Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025 | 227 | GlobeNewswire (Europe) | Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare... ► Artikel lesen | |
| 22.03.24 | Molecure: First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis | 160 | GlobeNewswire (Europe) | - OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,025 | -20,63 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,859 | -12,22 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile | Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive... ► Artikel lesen | |
| IMMATICS | 4,050 | -4,44 % | Bristol Myers Squibb und der große Hoffnungsträger - Immatics-Deal vor dem Aus | Vor knapp einem Jahr sorgte Bristol Myers Squibb mit einem Übernahme-Doppelschlag für Furore. Um Weihnachten herum kündigten die Amerikaner die Akquisitionen von Karuna Therapeutics und RayzeBio an.... ► Artikel lesen | |
| ALDEYRA | 5,886 | +19,61 % | Aldeyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MEDIFAST | 13,415 | -3,18 % | Medifast Aktie: Was heißt das jetzt konkret? | Die Medifast Aktie verzeichnete am 29. Oktober 2024 einen bescheidenen Kursanstieg von 2,47% auf 17,84 USD. Dieser leichte Aufschwung setzte sich am Folgetag fort, mit einem weiteren Plus von 3,81%... ► Artikel lesen | |
| PHARMING | 0,870 | +0,12 % | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13 | Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year... ► Artikel lesen | |
| COHERUS | 1,000 | -6,98 % | Coherus BioSciences, Inc.: Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 | ||
| ORUKA THERAPEUTICS | 11,100 | +13,27 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen | |
| INNOVIVA | 16,900 | -1,74 % | Innoviva GAAP EPS of $0.26, revenue of $91.8M | ||
| SIGA TECHNOLOGIES | 5,380 | -1,91 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,100 | +10,53 % | Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update | ||
| BRAINSTORM CELL THERAPEUTICS | 2,200 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Conference call planned for later in Q4 2024 to provide updates on NurOwn® program
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.... ► Artikel lesen | |
| DBV TECHNOLOGIES | 0,740 | -0,67 % | DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress | Châtillon, France, February 25, 2025
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT),... ► Artikel lesen | |
| LIQUIDIA | 15,040 | +0,67 % | Liquidia Corp - 8-K, Current Report | ||
| MATINAS BIOPHARMA | 0,579 | 0,00 % | Matinas BioPharma Holdings, Inc.: Matinas BioPharma Receives NYSE Noncompliance Notice | BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,24 % bei einem Aktienkurs von 2,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.
